Preparation method of recombinant III-type human collagen gynecological repair dressing
Through the preparation of recombinant human collagen gynecological repair dressings, a protective gel film was formed, which solved the problem that existing gynecological dressings could not form a film-like protective film, achieved effective isolation of the vaginal wall and symptom relief, and improved The protective effect of the dressing.
Patent Information
- Application Number
- CN202411170183.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
AI Technical Summary
Existing gynecological repair dressings are difficult to form a film-like protective film on the surface, resulting in the inability to effectively prevent or cure symptoms such as vaginitis and vulvar ulcers.
The preparation method of recombinant type III human collagen gynecological repair dressing was adopted, and the carbomer, recombinant type III human collagen, disodium ethylenediaminetetraacetate, hydroxyphenyl ethylphenyl ester and triethanolamine were mixed with purified water to form A protective gel membrane that physically isolates the vaginal walls and prevents bacteria from invading.
The formed gel membrane can effectively isolate external bacteria, relieve infections and symptoms caused by microbial disorders, such as odor, itching and inflammation, enhance protection to patients, and improve the practicality of the dressing.
Smart Images

Figure CN119015488A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of gynecological repair dressings, and in particular to a method for preparing a recombinant type III human collagen gynecological repair dressing. Background Art
[0002] The main function of gynecological repair dressings is to clean the female vagina to relieve the infection caused by vaginal microbial imbalance; general gynecological liquid dressings are similar to ordinary gynecological washes, mainly used for abnormal secretions, odor, vulvar itching and other symptoms, and can also promote the self-cleaning function of the vagina; so gynecological liquid dressings can be used for various types of vaginitis, vulvar ulcers, etc. The method of use is to use gynecological liquid dressings to directly clean the vulva or ulcer area, and can also be wet compressed on the vulvar ulcer area;
[0003] However, most existing gynecological repair dressings are difficult to form a film-like protective film on their surface, making it difficult to prevent or cure various symptoms such as vaginitis and vulvar ulcers;
[0004] Therefore, we proposed a method for preparing a recombinant type III human collagen gynecological repair dressing in order to solve the above-mentioned problems. Summary of the invention
[0005] The purpose of the present invention is to provide a method for preparing a recombinant type III human collagen gynecological repair dressing, so as to solve the problem raised in the above background technology that most gynecological repair dressings on the market currently cannot form a film-like protective film on their surface, making it difficult to prevent or cure various symptoms such as vaginitis and vulvar ulcers.
[0006] To achieve the above object, the present invention provides the following technical scheme: a method for preparing a recombinant type III human collagen gynecological repair dressing, wherein the raw materials of the dressing solvent are carbomer, recombinant type III human collagen, disodium edetate, ethyl hydroxybenzoate, triethanolamine, and purified water, wherein each 100 ml of the dressing comprises 0.2 g of recombinant type III human collagen, 0.03 g of carbomer, 0.05 g of disodium edetate, 0.05 g of ethyl hydroxybenzoate, and 0.1 ml of triethanolamine;
[0007] The preparation method of recombinant type III human collagen gynecological repair dressing, which is produced and developed in a 10,000-level purification room, includes the following steps:
[0008] Step 1: Prepare carbomer in a ratio of 1:100, heat and stir to dissolve, and then dissolve ethylparaben;
[0009] Step 2: Add a certain proportion of purified water to the dissolved carbomer and stir to dissolve; then add collagen, disodium edetate, ethylparaben and other ingredients in sequence, and finally add purified water to mix and stir to the prepared amount;
[0010] Step 3: Fill and seal the prepared contents;
[0011] Step 4: Take a sample of the contents in each mixing barrel after discharging to test the properties, pH value and dressing moldability. The sampling frequency is after each batch of discharging, and a total of 3 batches of continuous production are taken.
[0012] As a preferred technical solution of the present invention, filling is carried out according to batch production instructions, and a small amount of feeder is used for trial filling, so that the lotion or spray in the filling hopper is loaded into the feeder; and the cap is screwed on to make it sealed in the bottle to check the filling amount. Filling can only be carried out after the appearance and filling amount of the trial filling fully meet the requirements.
[0013] Since the dressing solution can form a protective gel film on the vaginal wall, the vaginal wall is physically isolated from the outside world, so that bacteria will not invade the inside of the protective film to cause damage to the vagina, and external bacteria will be prevented from invading the inside and causing damage to the vaginal wall, so as to alleviate the infection caused by microbial imbalance in the vagina, thereby avoiding the symptoms such as odor, itching, vaginitis and vulvar ulcers caused by the influence of microorganisms or bacteria, so that the dressing solution enhances the protection of patients and increases the practicality of the dressing solvent.
[0014] As a preferred technical solution of the present invention, after the finished product is manufactured, the average weight of ten feeders is randomly selected as the standard feeder weight weighed on the day; the loading control range: shall not be less than 90% of the labeled amount;
[0015] As a preferred technical solution of the present invention, according to the speed of the filling machine, during the rotation gap, the feeder is inserted into the base, the filling machine is loaded with lotion or spray, the cap is screwed, and heat-sealed, and finally sent to the outer room for packaging by the conveyor belt. During the operation, weigh every 15 minutes; record once every 1 hour; adjust the filling amount in time and keep records.
[0016] As a preferred technical solution of the present invention, when measuring the pH value, 20-30 ml of the finished product is measured and checked according to the pH value determination method. The pH value should be 4.5 to 7.5; wherein the determination principle is:
[0017] Principle: Use a pH meter (acidity meter) to measure the pH value of the aqueous solution of the drug to control the acidity and alkalinity of the drug; pH value is a convenient way to express the activity of hydrogen ions in the aqueous solution; pH value is defined as the negative logarithm of the activity of hydrogen ions (aH+) in the aqueous solution, that is, pH = -lgalH+, but the activity of hydrogen ions is difficult to accurately determine by experiment; for practical convenience, the pH value of the solution is determined by the following formula:
[0018] pH=pHs-E-Es / k
[0019] Where: E is the electromotive force of the primary cell containing the solution to be tested (pH), V;
[0020] Es is the electromotive force of the galvanic cell containing standard buffer solution (pHs), V;
[0021] k is a constant related to temperature (t, C);
[0022] k = 0.05916 + 0.000198 (t - 25).
[0023] Currently, the acidity meter is used directly for testing and the test results are directly output.
[0024] As a preferred technical solution of the present invention, triethanolamine can adjust the alkalinity and consistency; the color is light yellow, and the pH value is pH4.95.
[0025] As a preferred technical solution of the present invention, the batching, filling and sealing processes in the dressing solvent production process are carried out in a Class 100,000 clean area, and the processes related to this production are also in a clean area.
[0026] As a preferred technical solution of the present invention, during the filling process, it is divided into two types, one is lotion and the other is spray.
[0027] As a preferred technical solution of the present invention, the dressing solvent should be a colorless, white, off-white or light yellow solution in appearance, and the solution should be clear and free of mechanical impurities.
[0028] As a preferred technical solution of the present invention, since carbomer needs to maintain medium to weak alkalinity to have consistency, it cannot coexist with acidic skin-activating ingredients; in addition, carbomer is sensitive to ions, and ions cannot be added to the formula to ensure the consistency of carbomer to form a mucous membrane. After the dressing is applied, carbomer can form a protective film to effectively lock in moisture and other repair substances, so that human collagen, disodium ethylenediaminetetraacetic acid, ethylparaben, and triethanolamine are absorbed by the inner wall to prevent exposure. Through the formed protective film, a healing environment is formed for the female genitals, thereby playing a nursing role, and physically isolating it from the outside world to avoid the invasion of pathogenic microorganisms and bacteria, and can relieve the discomfort symptoms such as redness, swelling, dryness, odor, itching and inflammation caused or caused by diseases such as vaginitis and cervicitis.
[0029] Compared with the prior art, the present invention has the following beneficial effects:
[0030] Since the dressing solution can form a protective gel film on the vaginal wall, the vaginal wall is physically isolated from the outside world, so that bacteria will not invade the inside of the protective film to cause damage to the vagina, and external bacteria are prevented from invading the inside, so as to alleviate the infection of the vaginal wall caused by microbial imbalance, thereby avoiding external symptoms such as odor and itching, so that the dressing solution enhances the protection of the patient and increases the practicality of the dressing solution;
[0031] Through two different types of filling methods, lotion and spray, patients can choose different fillings according to different parts or symptoms when using the product, thereby increasing the convenience of use for patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 It is a preparation flow chart of the present invention. DETAILED DESCRIPTION
[0033] The technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments.
[0034] A method for preparing a recombinant type III human collagen gynecological repair dressing, wherein the raw materials of the dressing solvent are carbomer, recombinant type III human collagen, disodium edetate, ethyl hydroxybenzoate, triethanolamine, and purified water, wherein each 100 ml of the dressing comprises 0.2 g of recombinant type III human collagen, 0.03 g of carbomer, 0.05 g of disodium edetate, 0.05 g of ethyl hydroxybenzoate, and 0.1 ml of triethanolamine;
[0035] The preparation method of recombinant type III human collagen gynecological repair dressing, which is produced and developed in a 10,000-level purification room, includes the following steps:
[0036] Step 1: Prepare carbomer in a ratio of 1:100, heat and stir to dissolve, and then dissolve ethylparaben;
[0037] Step 2: Add a certain proportion of purified water to the dissolved carbomer and stir to dissolve; then add collagen, disodium edetate, ethylparaben and other ingredients in sequence, and finally add purified water to mix and stir to the prepared amount;
[0038] Step 3: Fill and seal the prepared contents;
[0039] Step 4: Take a sample of the contents in each mixing barrel after the material is discharged to test the properties, pH value and dressing moldability, etc. The sampling frequency is after each batch of material is discharged, and a total of 3 batches of continuous production are taken;
[0040] According to the batch production instructions, fill the bottles with a small amount of feeders for trial filling, and let the lotion or spray in the hopper be loaded into the feeders; and after screwing the cap, seal it in the bottle to check the filling amount. Filling can be carried out only after the appearance and filling amount of the trial filling fully meet the requirements; after the finished product is made, take the average weight of ten feeders as the standard feeder weight weighed on the day; the filling amount control range: shall not be less than 90% of the marked amount; according to the speed of the filling machine, during the rotation gap, insert the feeder into the base, and the filling machine will load the lotion or spray, screw the cap, heat seal it, and finally send it to the outer room for packaging by the conveyor belt. During the operation, weigh it every 15 minutes; record it once every hour; adjust the filling amount in time and keep records;
[0041] When measuring the pH value, take 20-30 ml of the finished product and check it according to the pH value determination method. The pH value should be 4.5-7.5. The determination principle is:
[0042] Principle: Use a pH meter (acidity meter) to measure the pH value of the aqueous solution of the drug to control the acidity and alkalinity of the drug; pH value is a convenient way to express the activity of hydrogen ions in the aqueous solution; pH value is defined as the negative logarithm of the activity of hydrogen ions (aH+) in the aqueous solution, that is, pH = -lgalH+, but the activity of hydrogen ions is difficult to accurately determine by experiment; for practical convenience, the pH value of the solution is determined by the following formula:
[0043] pH=pHs-E-Es / k
[0044] Where: E is the electromotive force of the primary cell containing the solution to be tested (pH), V;
[0045] Es is the electromotive force of the galvanic cell containing standard buffer solution (pHs), V;
[0046] k is a constant related to temperature (t, C);
[0047] k = 0.05916 + 0.000198 (t-25);
[0048] At present, the acidity meter is directly used for testing, and the test results are directly output;
[0049] Triethanolamine can adjust the alkalinity and consistency; the color is light yellow, and the pH value is PH4.95;
[0050] The process water used in the production of medical recombinant type III human collagen gynecological repair dressings is purified water, which must comply with the purified water quality standards of the Chinese Pharmacopoeia (2020 edition);
[0051] Since carbomer needs to maintain a medium to weak alkalinity to have a consistency, it cannot coexist with acidic skin-revitalizing ingredients. In addition, carbomer is sensitive to ions, and ions cannot be added to the formula to ensure the consistency of carbomer to form a mucous membrane. After the dressing is applied, carbomer can form a protective film to effectively lock in moisture and other repair substances, so that human collagen, disodium edetate, ethylparaben, and triethanolamine are absorbed by the inner wall to prevent exposure. Through the formed protective film, a healing environment is formed for the female vulva, thereby playing a nursing role, and physically isolating it from the outside world to avoid the invasion of pathogenic microorganisms and bacteria. It can relieve discomfort symptoms such as redness, swelling, dryness, odor, itching and inflammation caused or caused by diseases such as vaginitis and cervicitis.
[0052] The dressing solvent production process includes batching, filling and sealing processes in a Class 100,000 clean area, and the production-related processes are also in a clean area. In the filling process, there are two types of models, one is a lotion and the other is a spray. The dressing solvent should be a colorless, white, off-white or light yellow solution, and the solution should be clear and free of mechanical impurities, as shown in Table 1:
[0053]
[0054]
[0055] Table 1
[0056] The following are the test methods and data:
[0057] Filling volume: When the volume is less than 20mL, the filling volume of each container shall not be less than 93% of the labeled filling volume; when the volume is between 20mL and 50mL, the filling volume of each container shall not be less than 95% of the labeled filling volume; when the volume is more than 50mL, the filling volume of each container shall not be less than 97% of the labeled filling volume; the average filling volume shall not be less than the labeled filling volume;
[0058] Formulate sealing requirements based on product characteristics:
[0059] Sealing inspection basis: whether the sealing part of the product is rotated in place and whether there is any damage, so the bottle mouth is inverted for 24 hours for inspection; the product is inverted for 24 hours, and the container should be well sealed without leakage; take 3 bottles of the test product, invert the product for 24 hours, and it should meet the requirements;
[0060] Basis for spray performance inspection: Spray-type products use the liquid in the spray bottle to create a pressure difference inside the bottle that is higher than outside the bottle by pressing, so that the solution in the container is sprayed out. Check whether the nozzle is intact and has a spray function by pressing, and check the spray effect by spraying on filter paper;
[0061] Spray performance: It should be in a spray shape, and the spray points on the filter paper should be distributed in a scattered manner;
[0062] Test method: Take 3 bottles of the test sample, place a filter paper with a diameter of 10 cm 25 cm away from the spray nozzle, press and spray 3 times each time, the result should meet the requirements;
[0063] Film forming properties:
[0064] After evenly smearing, place in a 37℃±1℃ constant temperature box to dry for 30 minutes, and a thin film should be formed; apply the product on the inner surface of the culture dish, evenly smear it into a thin layer, and place in a 37℃±1℃ constant temperature box to dry for 30 minutes;
[0065] Protein identification: According to the fourth method of protein in the fourth part of the 2020 edition of the Chinese Pharmacopoeia, the BCA method should react with copper-BCA test solution to generate a purple complex solution; measure 10mL of sample and place it in a test tube, add 1mL of copper-BCA test solution, react in a 37℃±1℃ water bath for 2min, observe the color of the solution, and the protein content should be no less than 50μg / mL;
[0066] This dressing solvent is a non-sterile product. The biological requirements are based on the characteristic microbial limits of the product. The total aerobic bacteria count shall not exceed 100 cfu / mL, the total mold and yeast count shall not exceed 10 cfu / mL, and the controlled bacteria Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans shall not be detected.
[0067] Cytotoxicity assay:
[0068] Take the product and add the extraction medium at a ratio of 0.2g / ml. The extraction medium is MEM medium containing serum. Extract at (37±1)℃ for (24±2)h to prepare the test solution. The test solution is tested according to the method specified in 8.2 of GB / T16886.5-2017. The cytotoxicity should not be greater than level 2.
[0069] Test method:
[0070] S1: Cell suspension preparation and inoculation
[0071] Digest the vigorously growing cells that have been cultured for 48h to 72h with digestion solution and add cell culture medium. Mix well by pipetting and counting, and then prepare the cell suspension to a density of 1x105 cells / ml and inoculate it in a 96-well plate; add 100ul of culture medium to each well outside the test area of the 96-well plate, and inoculate 100l of the prepared cell suspension to each well in the remaining middle;
[0072] Place in CO2 incubator and culture for 24h (37C, 5% CO2);
[0073] S2: Add test solution
[0074] After 24 hours, the original culture medium added to the cell wells was discarded, 12 wells were added with blank control solution as blank control, 6 wells were added with negative control solution, 6 wells were added with positive control solution, and the remaining 6 wells were added with sample extract solution, and the cells were placed in a CO2 incubator for 24 hours. The experimental cell line was mouse fibroblasts, and the layout of the plates is shown in the table below.
[0075] Table 2:
[0076]
[0077]
[0078] Note: B is blank control; NC is negative control; PC is positive control; C is sample extract; b is culture medium;
[0079] Table 2
[0080] After the culture, the changes in cell morphology, vacuole formation, shedding, cell lysis and membrane integrity were observed under a microscope and graded according to the evaluation criteria, as shown in Table 3:
[0081]
[0082] Table 3
[0083] Conclusion: The cytotoxicity of the sample extract group was graded as level 2, which showed mild cytotoxicity according to GB / T16886.5-2017.
[0084] Skin sensitization (occluded patch test):
[0085] Test method: Take the sample and apply it topically to the upper left back of each animal. Remove any occlusive bandage-like fixation and patch after (6±0.5) hours. Repeat this step for 3 consecutive days in 1 week, and operate in the same way for 3 weeks. Use the control solution and operate in the same way for the control animals. (14±1) days after the last induction patch, stimulate all test animals and control animals with the sample, soak a 2.5cmX2.5cm patch in the sample, and apply it topically to the untested part of each animal where the hair is removed. Remove the fixation, occlusive bandage and patch after (6±0.5) hours. Observe the skin erythema and edema reaction at the stimulated part of the guinea pig at (24+2) hours and (48±2) hours after the patch is removed, and describe and grade them.
[0086] Clinical observation: There were no obvious abnormalities in the guinea pigs during the experimental observation period;
[0087] Sensitization results: The skin of the stimulated area of the animals in the sample group and the control group was observed at (24±2)h and (48±2)h after stimulation. No obvious erythema and edema were found. According to the Magnuson and Kligman grading standard, it was grade 0, as shown in Table 4:
[0088]
[0089]
[0090] Table 4
[0091] Under the conditions of this test, no erythema and edema were found on the skin of the stimulated area of the animals in the sample group, which was graded as 0 according to the Magnusson and Kligman classification, and the positive incidence rate was 0%.
[0092] Vaginal irritation test:
[0093] Test method: Place the experimental rabbit in a fixture, expose the administration site, administer the sample and control solution vaginally through a catheter at a rate of 1 ml / rabbit, once a day for 5 consecutive days, and painlessly kill the animal (24±2) hours after the last contact, and take the sample contact site for administration, once a day for 5 consecutive days, and painlessly kill the animal (24±2) hours after the last contact, and take the sample contact site;
[0094] Results: The stimulation index of the sample group was 0, and the degree of reaction was none.
[0095] Transdermal test (broken skin):
[0096] According to GB / T27818-2011, the medical recombinant type II human collagen gynecological repair dressing was tested for permeation through damaged skin. Samples were taken at 1h, 2h, 4h, 8h, and 24h, and the collagen content in the receiving pool was measured using a high-performance liquid chromatograph. The test results showed that within 24h, no permeation absorption of medical recombinant type I1 human collagen from damaged skin was found in the gynecological repair dressing;
[0097] The experiment was conducted on pigs aged 2-3 months. After the live pigs were anesthetized, professional shaving tools were used to remove the hair on the pig abdomen as cleanly as possible. During the removal process, care was taken not to scratch the pig skin to ensure the integrity of the experiment. A scalpel was used to create wounds that did not damage the dermis. The pig skin was cut into a size of about 3x3cm2, and the subcutaneous tissue and fat were carefully removed to try to make the pig skin thickness less than 1mm. After the treatment was completed, the pig skin was fully rinsed with physiological saline and used for in vitro transdermal experiments.
[0098] Rinse the pigskin with saline and then dry it with filter paper for later use; place the prepared ex vivo pigskin on the diffusion pool with the skin stratum corneum facing up; pour the medical recombinant type I human collagen gynecological repair dressing into the supply pool and adhere it to the ex vivo pigskin, add pH7.1 PBS solution to the receiving pool, so that the liquid surface just touches the skin, cover the receiving pool with a cover, fix it with a horseshoe clamp, place it in a 32+1℃ constant temperature water bath, and stir it continuously with a magnetic stirrer at a stirring speed of 300r / min; take 1.0mL of receiving solution at 1h, 2h, 4h, 8h, and 24h after coating, add an equal amount of receiving solution to the receiving pool after sampling, filter it through a 0.22um microporous filter membrane, and store it in cold storage for testing;
[0099] The standard working solution and the receiving solution at 1h, 2h, 4h, 8h, and 24h were used to determine collagen in accordance with the instrument conditions in 4.3. The results showed that the collagen had good linearity within the detection concentration range, and the correlation coefficient was greater than 0.99. Therefore, the linear correlation results were acceptable. The transdermal test results are shown in Table 5:
[0100]
[0101] Table 5
[0102] Thereby completing a series of tasks, the contents not described in detail in this specification belong to the prior art known to professional and technical personnel in this field.
[0103] It will be apparent to those skilled in the art that the invention is not limited to the details of the exemplary embodiments described above and that the invention can be implemented in other specific forms without departing from the spirit or essential features of the invention. Therefore, the embodiments should be considered exemplary and non-limiting in all respects, and the scope of the invention is defined by the appended claims rather than the foregoing description, and it is intended that all variations falling within the meaning and scope of the equivalent elements of the claims be included in the invention. Any reference numeral in a claim should not be considered as limiting the claim to which it relates.
Claims
1. A method for preparing a recombinant type III human collagen gynecological repair dressing, It is characterized in that The dressing solvent is made of carbomer, recombinant type III human collagen, disodium edetate, ethyl hydroxybenzoate, triethanolamine, and purified water, wherein each 100 ml of the dressing includes 0.2 g of recombinant type III human collagen, 0.03 g of carbomer, 0.05 g of disodium edetate, 0.05 g of ethyl hydroxybenzoate, and 0.1 ml of triethanolamine; The preparation method of the recombinant type III human collagen gynecological repair dressing comprises the following steps: Step 1: Prepare a clean area, place the ingredients and equipment inside the clean area, then heat and stir the prepared Carbomer at a ratio of 1:100 to dissolve, and then dissolve ethylparaben; Step 2: Add a certain proportion of purified water to the dissolved carbomer and stir to dissolve; then add collagen, disodium edetate, ethylparaben and other ingredients in sequence, and finally add purified water to mix and stir to the prepared amount; Step 3: Fill and seal the prepared contents; Step 4: Take a sample of the contents in each mixing barrel after discharging to test the properties, pH value and dressing moldability. The sampling frequency is after each batch of discharging, and a total of 3 batches of continuous production need to be sampled.
2. The method for preparing the recombinant type III human collagen gynecological repair dressing according to claim 1, It is characterized in that Carry out filling according to batch production instructions, use a small amount of feeder for trial filling, and allow the lotion or spray in the hopper to be loaded into the feeder; and after screwing the cap, seal it in the bottle to check the filling quantity. Filling can only be carried out after the appearance and filling quantity of the trial filling fully meet the requirements.
3. The method for preparing the recombinant type III human collagen gynecological repair dressing according to claim 1, It is characterized in that After the finished product is made, the average weight of ten feeders is taken as the standard feeder weight for the day; the filling quantity control range: not less than 90% of the marked quantity; According to the speed of the filling machine, insert the feeder into the base during the rotation gap, and the filling machine will load the lotion or spray, screw the cap, heat seal, and finally send it to the outer room for packaging by the conveyor belt. During the operation, weigh it every 15 minutes and record it once every hour; adjust the filling amount in time and keep records.
4. The method for preparing the recombinant type III human collagen gynecological repair dressing according to claim 1, It is characterized in that When measuring the pH value, measure 20-30 ml of the finished product and check it according to the pH value determination method. The pH value should be 4.5-7.
5. Currently, it can be directly tested with an acidity meter and the test results can be directly output.
5. The method for preparing the recombinant type III human collagen gynecological repair dressing according to claim 1, It is characterized in that Triethanolamine can adjust alkalinity and consistency; its color is light yellow and its pH value is 4.
95.
6. The method for preparing the recombinant type III human collagen gynecological repair dressing according to claim 1, It is characterized in that The batching, filling and sealing processes in the dressing solvent production process are carried out in a 100,000-class clean area, and all processes related to this production are also in a clean area.
7. The method for preparing the recombinant type III human collagen gynecological repair dressing according to claim 1, It is characterized in that During the filling process, it is divided into two types, type one is lotion and type two is spray.
8. The method for preparing the recombinant type III human collagen gynecological repair dressing according to claim 1, It is characterized in that The dressing solvent should appear as a colorless, white, off-white or light yellow solution, and the solution should be clear and free of mechanical impurities.
9. The method for preparing the recombinant type III human collagen gynecological repair dressing according to claim 1, It is characterized in that Since carbomer needs to maintain a medium to weak alkalinity to have a consistency, it cannot coexist with acidic skin-revitalizing ingredients. In addition, carbomer is sensitive to ions, and ions cannot be added to the formula to ensure the consistency of carbomer to form a mucous membrane. After the dressing is applied, carbomer can form a protective film to effectively lock in moisture and other repair substances, so that human collagen, disodium edetate, ethylparaben, and triethanolamine are absorbed by the inner wall to prevent exposure. Through the formed protective film, a healing environment is formed for the female vulva, thereby playing a nursing role, and physically isolating it from the outside world to avoid the invasion of pathogenic microorganisms and bacteria. It can relieve discomfort symptoms such as redness, swelling, dryness, odor, itching and inflammation caused or caused by diseases such as vaginitis and cervicitis.
